Xiangqun Song

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin et al. · Journal of Clinical Oncology · 2013 · 774 citations · Full text

Medicine, Oncology, Pharmacology +15

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · Journal of Clinical Oncology · 2015 · 390 citations · Full text

Medicine, Oncology, Pharmacology +9

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Li Zhang, Shenglin Ma, Xiangqun Song et al. · The Lancet Oncology · 2012 · 227 citations

Medicine, Oncology, Pharmacology +7

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Jung Shin Lee, Sang‐We Kim, José Rodrigues-Pereira et al. · European Journal of Cancer · 2013 · 78 citations

Medicine, Oncology, Pharmacology +9

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Hongyun Zhao, Yun Fan, Shenglin Ma et al. · Journal of Thoracic Oncology · 2015 · 44 citations · Full text

Medicine, Oncology, Pharmacology +14